Doaa Salah Hegab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Doaa Salah Hegab has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
El-Sayed Shaaban Hewedy
Tanta Univ, Fac Med, Dept & Venereol Dept, Tanta, Egypt
2 shared publications- Fatma Abdel Ghafar AbdRabo
Tanta Univ, Fac Med, Dept Dermatol & Venereol, Tanta, Egypt
2 shared publications - Gamal Mohamed El Maghraby
Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
2 shared publications - Ibrahim Ali Kabbash
Tanta University
2 shared publications - Manal Bosseila
Dermatology Department, Faculty of Medicine, Cairo University, Egypt
2 shared publications - Mohamed Attia Attia
Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt
2 shared publications
Latest Publications
- 7 December 2024
- Published byĀ Springer NatureĀ inĀ Archives of Dermatological Research
- Vol.Ā 317 Ā (1) , 83
Dermoscopic diagnostic algorithm for hypopigmented/ depigmented skin diseases
- 7 December 2024
- Published byĀ Springer NatureĀ inĀ Archives of Dermatological Research
- Vol.Ā 317 Ā (1) , 83
Dermoscopic diagnostic algorithm for hypopigmented/ depigmented skin diseases
- 23 August 2024
- Published byĀ Springer NatureĀ inĀ Archives of Dermatological Research
- Vol.Ā 316 Ā (8) , 1-11
Evaluation of diagnostic accuracy of dermoscopy in some common hypopigmented skin diseases
Background Diagnosis of cutaneous hypopigmentation can sometimes be challenging. Dermoscopy may play a role in identifying hypo or-depigmented dermatoses. The aim was to investigate which dermoscopic criteria represent potent indicators for the diagnosis of vitiligo, nevus depigmentosus, pityriasis alba, hypopigmented pityriasis versicolor, idiopathic guttate hypomelanosis, hypopigmented mycosis fungoides (MF), lichen sclerosus et atrophicus and ash leaf hypopigmented macules of tuberous sclerosis, and evaluate their diagnostic accuracy. 168 individuals diagnosed with one of these hypopigmented disorders were evaluated for the presence or absence of predetermined dermoscopic criteria. Evaluation of dermatoscopic characteristics in each condition and analysis for sensitivity and specificity of dermatoscopic diagnosis in these hypopigmented lesions was performed. The starburst pattern, micro-koebnerization, and trichrome pattern were unique to vitiligo diagnosis. Vitiligo had higher comet-tail appearance, perifollicular pigmentation, and perilesional hyperpigmentation than other hypopigmented illnesses. Other hypopigmented lesions had greater incidence of amoeboid pattern, faint or diminished pigment network, islands of pigmentation, ill-defined boundaries, pseudopods, and widespread scaling than vitiligo. Finally, perifollicular scaling, comedo-like openings, blue-gray specks, and fibrotic regions excluded vitiligo. Dermoscopy can help identify common hypopigmented skin lesions and reduce the need for skin biopsy. Nevus depigmentosus, pityriasis alba and idiopathic guttate hypomelanosis were the top three hypopigmented dermatoses that could be diagnosed by dermoscopy with 100% sensitivity. Vitiligo was in the second rank (94.7%), followed by lichen sclerosis et atrophicus (93.3%) then hypopigmented MF at 81.2% sensitivity. Dermoscopy sensitivity was lowest in pityriasis versicolor and ash leaf macules of tuberous sclerosis (52.6% and 46.7%, respectively).
- 23 August 2024
- Published byĀ Springer NatureĀ inĀ Archives of Dermatological Research
- Vol.Ā 316 Ā (8) , 1-11
Evaluation of diagnostic accuracy of dermoscopy in some common hypopigmented skin diseases
Background Diagnosis of cutaneous hypopigmentation can sometimes be challenging. Dermoscopy may play a role in identifying hypo or-depigmented dermatoses. The aim was to investigate which dermoscopic criteria represent potent indicators for the diagnosis of vitiligo, nevus depigmentosus, pityriasis alba, hypopigmented pityriasis versicolor, idiopathic guttate hypomelanosis, hypopigmented mycosis fungoides (MF), lichen sclerosus et atrophicus and ash leaf hypopigmented macules of tuberous sclerosis, and evaluate their diagnostic accuracy. 168 individuals diagnosed with one of these hypopigmented disorders were evaluated for the presence or absence of predetermined dermoscopic criteria. Evaluation of dermatoscopic characteristics in each condition and analysis for sensitivity and specificity of dermatoscopic diagnosis in these hypopigmented lesions was performed. The starburst pattern, micro-koebnerization, and trichrome pattern were unique to vitiligo diagnosis. Vitiligo had higher comet-tail appearance, perifollicular pigmentation, and perilesional hyperpigmentation than other hypopigmented illnesses. Other hypopigmented lesions had greater incidence of amoeboid pattern, faint or diminished pigment network, islands of pigmentation, ill-defined boundaries, pseudopods, and widespread scaling than vitiligo. Finally, perifollicular scaling, comedo-like openings, blue-gray specks, and fibrotic regions excluded vitiligo. Dermoscopy can help identify common hypopigmented skin lesions and reduce the need for skin biopsy. Nevus depigmentosus, pityriasis alba and idiopathic guttate hypomelanosis were the top three hypopigmented dermatoses that could be diagnosed by dermoscopy with 100% sensitivity. Vitiligo was in the second rank (94.7%), followed by lichen sclerosis et atrophicus (93.3%) then hypopigmented MF at 81.2% sensitivity. Dermoscopy sensitivity was lowest in pityriasis versicolor and ash leaf macules of tuberous sclerosis (52.6% and 46.7%, respectively).
- Open Access
- 31 July 2023
- Published byĀ Mattioli1885Ā inĀ Dermatology Practical & Conceptual
- Vol.Ā 13 Ā (3) , e2023195
Efficacy and Safety of Topical Tranexamic Acid Alone or in Combination with Either Fractional Carbon Dioxide Laser or Microneedling for the Treatment of Melasma
Introduction: Tranexamic acid (TXA) is a promising treatment modality for melasma. Microneedling (MN) and fractional carbon dioxide (CO2) laser were reported to enhance TXA transepidermal delivery. Objectives: To compare efficacy and safety of topical TXA alone or in combination with either fractional CO2 laser or MN for treatment of melasma. Methods: Thirty females with facial melasma were divided randomly into 3 equal groups after excluding pregnant and lactating women and those using oral contraceptives or other hormonal therapy. Patients of group A were treated with fractional CO2 laser and those of group B were treated with MN (4 sessions, 3 weeks apart for both) with immediate topical application of TXA 5% solution after sessions and daily application of 5% TXA cream for both groups. Patients of group C were treated by topical daily application of TXA 5% cream. Evaluation was done by modified melasma area and severity index scores (mMASI), patient satisfaction and dermoscopy. Results: Statistically significant improvement of mMASI was reported in all studied groups with a significantly better improvement in patients of groups A and B than those of group C, meanwhile the difference between groups A and B was statistically insignificant. Conclusions: Topical TXA is a safe and fairly effective treatment modality for facial melasma. Combining TXA with either fractional CO2 laser or MN yielded significantly better improvement than when used alone. Fractional CO2 laser carries the risk of post-inflammatory hyperpigmentation in patients with skin types III and IV and requires meticulous patient selection.
- 31 July 2023
- Published byĀ Mattioli1885Ā inĀ Dermatology Practical & Conceptual
- Vol.Ā 13 Ā (3) , e2023195
Open AccessEfficacy and Safety of Topical Tranexamic Acid Alone or in Combination with Either Fractional Carbon Dioxide Laser or Microneedling for the Treatment of Melasma
Introduction: Tranexamic acid (TXA) is a promising treatment modality for melasma. Microneedling (MN) and fractional carbon dioxide (CO2) laser were reported to enhance TXA transepidermal delivery. Objectives: To compare efficacy and safety of topical TXA alone or in combination with either fractional CO2 laser or MN for treatment of melasma. Methods: Thirty females with facial melasma were divided randomly into 3 equal groups after excluding pregnant and lactating women and those using oral contraceptives or other hormonal therapy. Patients of group A were treated with fractional CO2 laser and those of group B were treated with MN (4 sessions, 3 weeks apart for both) with immediate topical application of TXA 5% solution after sessions and daily application of 5% TXA cream for both groups. Patients of group C were treated by topical daily application of TXA 5% cream. Evaluation was done by modified melasma area and severity index scores (mMASI), patient satisfaction and dermoscopy. Results: Statistically significant improvement of mMASI was reported in all studied groups with a significantly better improvement in patients of groups A and B than those of group C, meanwhile the difference between groups A and B was statistically insignificant. Conclusions: Topical TXA is a safe and fairly effective treatment modality for facial melasma. Combining TXA with either fractional CO2 laser or MN yielded significantly better improvement than when used alone. Fractional CO2 laser carries the risk of post-inflammatory hyperpigmentation in patients with skin types III and IV and requires meticulous patient selection.
- Open Access
- 31 July 2023
- Published byĀ Mattioli1885Ā inĀ Dermatology Practical & Conceptual
- Vol.Ā 13 Ā (3) , e2023192
Topical Oxybutynin 3% Gel versus Aluminum Chloride 15% Lotion in Treatment of Primary Focal Hyperhidrosis
Introduction: Hyperhidrosis is excessive sweating beyond thermoregulatory needs. It is a potentially disabling condition with challenging management. Aluminum chloride is the established topical treatment; however, response remains unsatisfactory. Oxybutynin is an anticholinergic drug that stands as a therapeutic chance for hyperhidrosis. Objectives: comparing the efficacy of topical oxybutynin 3% gel versus aluminum chloride 15% lotion in treatment of primary focal hyperhidrosis. Methods: Forty patients with hyperhidrosis were randomly distributed into 2 equal groups treated by either topical oxybutynin 3% gel or topical aluminum chloride 15% lotion once daily night application for 4 weeks (both groups). Evaluation was done at 2 and 4 weeks of treatment and after 1 month of the end of treatment for follow up by Minor iodine starch test, hyperhidrosis disease severity scale (HDSS) and dermatology life quality index (DLQI). Results: Both treatment modalities were effective with insignificant differences between patients of both groups regarding improvement in Minor iodine starch test and HDSS after 2 weeks of treatment (P = 0.561, 0.33 respectively). Oxybutynin 3% gel yielded significantly better improvement of Minorās test, HDSS and patientās quality of life at the end of 4 weeks of treatment with lower recurrence rate than aluminum chloride 15% lotion at 1 month follow up. Minimal adverse effects were noted in both studied groups. Conclusions: Oxybutynin 3% gel could be considered as a promising treatment modality for hyperhidrosis with higher efficacy than aluminum chloride 15% lotion and lower recurrence rate.
- 31 July 2023
- Published byĀ Mattioli1885Ā inĀ Dermatology Practical & Conceptual
- Vol.Ā 13 Ā (3) , e2023192
Open AccessTopical Oxybutynin 3% Gel versus Aluminum Chloride 15% Lotion in Treatment of Primary Focal Hyperhidrosis
Introduction: Hyperhidrosis is excessive sweating beyond thermoregulatory needs. It is a potentially disabling condition with challenging management. Aluminum chloride is the established topical treatment; however, response remains unsatisfactory. Oxybutynin is an anticholinergic drug that stands as a therapeutic chance for hyperhidrosis. Objectives: comparing the efficacy of topical oxybutynin 3% gel versus aluminum chloride 15% lotion in treatment of primary focal hyperhidrosis. Methods: Forty patients with hyperhidrosis were randomly distributed into 2 equal groups treated by either topical oxybutynin 3% gel or topical aluminum chloride 15% lotion once daily night application for 4 weeks (both groups). Evaluation was done at 2 and 4 weeks of treatment and after 1 month of the end of treatment for follow up by Minor iodine starch test, hyperhidrosis disease severity scale (HDSS) and dermatology life quality index (DLQI). Results: Both treatment modalities were effective with insignificant differences between patients of both groups regarding improvement in Minor iodine starch test and HDSS after 2 weeks of treatment (P = 0.561, 0.33 respectively). Oxybutynin 3% gel yielded significantly better improvement of Minorās test, HDSS and patientās quality of life at the end of 4 weeks of treatment with lower recurrence rate than aluminum chloride 15% lotion at 1 month follow up. Minimal adverse effects were noted in both studied groups. Conclusions: Oxybutynin 3% gel could be considered as a promising treatment modality for hyperhidrosis with higher efficacy than aluminum chloride 15% lotion and lower recurrence rate.
- 1 October 2021
- Published byĀ MedknowĀ inĀ Dermatologica Sinica
- Vol.Ā 39 Ā (4) , 198-201
Circulating follicular T-helper cells in patients with nonsegmental vitiligo
Vitiligo is a common depigmenting dermatosis with an autoimmune background. Circulating T-follicular helper (Tfh) cells are reported to increase and correlate with disease activity and autoantibody production in several human autoimmune diseases. The potential contribution of Tfh cells in vitiligo pathogenesis has not been well elucidated yet. Hence, this study aimed to evaluate the frequency of circulating Tfh cells in patients with nonsegmental vitiligo (NSV) in comparison to normal healthy subjects to detect their possible role in vitiligo pathogenesis. Venous blood samples were obtained from 25 patients with NSV and 20 age- and sex-matched healthy controls to determine the level of circulating Tfh cells (CD3+ CD4+ CXCR5+ PD-1+ T cell population), by flowcytometry. The frequency of peripheral CXCR5+ PD-1+ lymphocytes which are CD3+ CD4+ was significantly augmented in vitiligo patients than controls. It showed a significant positive correlation with vitiligo disease severity and activity estimated by Vitiligo Area Scoring Index and Vitiligo Disease Activity scores, respectively. These results emphasize on the potential role of Tfh cells in the pathogenesis, extent, and severity of NSV. Antagonizing the autoimmune initiating action of Tfh cells population or targeting their cytokine secretion might offer a helpful future tool for the treatment of patients with NSV particularly in active cases.
- 1 October 2021
- Published byĀ MedknowĀ inĀ Dermatologica Sinica
- Vol.Ā 39 Ā (4) , 198-201
Circulating follicular T-helper cells in patients with nonsegmental vitiligo
Vitiligo is a common depigmenting dermatosis with an autoimmune background. Circulating T-follicular helper (Tfh) cells are reported to increase and correlate with disease activity and autoantibody production in several human autoimmune diseases. The potential contribution of Tfh cells in vitiligo pathogenesis has not been well elucidated yet. Hence, this study aimed to evaluate the frequency of circulating Tfh cells in patients with nonsegmental vitiligo (NSV) in comparison to normal healthy subjects to detect their possible role in vitiligo pathogenesis. Venous blood samples were obtained from 25 patients with NSV and 20 age- and sex-matched healthy controls to determine the level of circulating Tfh cells (CD3+ CD4+ CXCR5+ PD-1+ T cell population), by flowcytometry. The frequency of peripheral CXCR5+ PD-1+ lymphocytes which are CD3+ CD4+ was significantly augmented in vitiligo patients than controls. It showed a significant positive correlation with vitiligo disease severity and activity estimated by Vitiligo Area Scoring Index and Vitiligo Disease Activity scores, respectively. These results emphasize on the potential role of Tfh cells in the pathogenesis, extent, and severity of NSV. Antagonizing the autoimmune initiating action of Tfh cells population or targeting their cytokine secretion might offer a helpful future tool for the treatment of patients with NSV particularly in active cases.
- 17 June 2021
- Published byĀ WileyĀ inĀ Journal of Cosmetic Dermatology
- Vol.Ā 20 Ā (10) , 3330-3340
Intralesional pentoxifylline, triamcinolone acetonide, and their combination for treatment of keloid scars
Background: Keloids are common fibroproliferative tumors, and their treatment still represents a dilemma. Intralesional triamcinolone acetonide (TAC) injection is effective, but frequently associated with side effects. Pentoxifyllin (PTX) is a vasodilator, antiāinflammatory, and antifibrotic agent. Its intralesional injection in keloids has not been evaluated yet.Aims: Evaluating the efficacy and safety of intralesional PTX versus intralesional TAC and their combination for treatment of keloids.Patients/Methods: Thirty patients with keloids were divided into three equal groups and treated by intralesional injection of TAC, PTX, or their combination (admixed in 1:1 ratio). Injections were repeated every 3 weeks until lesional flattening or for maximum of 5 sessions. The evaluation was done using the Vancouver Scar Scale and the Verbal Rating Scale for pain and itching.Results: A significant improvement in VSS was detected in all groups. Significantly better improvements in keloid height, pliability, pain, and itching were detected in the TAC and combination groups than in the PTX group. There was a significantly higher incidence of side effects (atrophy, hypopigmentation, telangiectasia, and precipitation of TAC) in the TAC group than in the combination group, while no side effects were reported in the PTX group. A statistically significant reduction in the number of treatment sessions (required to achieve best results) was detected in patients in the combination group.Conclusions: Intralesional injection of PTX is a potentially helpful, safe, and wellātolerated therapeutic tool for keloids, but with lower efficacy than intralesional TAC when used solely. Combining PTX and TAC produces significantly better results for keloid treatment and lowers the risk of TACāinduced side effects.
- 17 June 2021
- Published byĀ WileyĀ inĀ Journal of Cosmetic Dermatology
- Vol.Ā 20 Ā (10) , 3330-3340
Intralesional pentoxifylline, triamcinolone acetonide, and their combination for treatment of keloid scars
Background: Keloids are common fibroproliferative tumors, and their treatment still represents a dilemma. Intralesional triamcinolone acetonide (TAC) injection is effective, but frequently associated with side effects. Pentoxifyllin (PTX) is a vasodilator, antiāinflammatory, and antifibrotic agent. Its intralesional injection in keloids has not been evaluated yet.Aims: Evaluating the efficacy and safety of intralesional PTX versus intralesional TAC and their combination for treatment of keloids.Patients/Methods: Thirty patients with keloids were divided into three equal groups and treated by intralesional injection of TAC, PTX, or their combination (admixed in 1:1 ratio). Injections were repeated every 3 weeks until lesional flattening or for maximum of 5 sessions. The evaluation was done using the Vancouver Scar Scale and the Verbal Rating Scale for pain and itching.Results: A significant improvement in VSS was detected in all groups. Significantly better improvements in keloid height, pliability, pain, and itching were detected in the TAC and combination groups than in the PTX group. There was a significantly higher incidence of side effects (atrophy, hypopigmentation, telangiectasia, and precipitation of TAC) in the TAC group than in the combination group, while no side effects were reported in the PTX group. A statistically significant reduction in the number of treatment sessions (required to achieve best results) was detected in patients in the combination group.Conclusions: Intralesional injection of PTX is a potentially helpful, safe, and wellātolerated therapeutic tool for keloids, but with lower efficacy than intralesional TAC when used solely. Combining PTX and TAC produces significantly better results for keloid treatment and lowers the risk of TACāinduced side effects.
- 22 June 2020
- Published byĀ Taylor & FrancisĀ inĀ Journal of Dermatological Treatment
- Vol.Ā 33 Ā (2) , 798-804
Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma
Background: Tranexamic acid is a promising drug for melasma treatment, but its topical formulation has limited efficacy. Its use as liposome based cream or in combination with other modalities might help to achieve better results. Objective: Comparing efficacy of topical tranexamic acid 5% in liposome base alone versus its combination with intradermal platelet rich plasma (PRP) for melisma treatment. Methods: Forty female patients with melasma were divided randomly into 2 equal groups who were treated with topical tranexamic acid 5% cream twice daily for 12 weeks and group B received additional intradermal injections of PRP every 3 weeks throughout the treatment period. Evaluation was done through modified MASI score and patient satisfaction after one month from the end of treatment. Results: Both groups showed significant improvement of modified MASI score after treatment. Significantly better treatment response and patient satisfaction were detected in patients of group B (p = .024, .029). The side effects of PRP were mild and tolerable and tranexamic acid was well tolerated. Conclusion: 5% topical tranexamic acid in liposome base is thought to be safe and effective modality for treatment of melasma. PRP is advisable as an autologous safe elixir which boosts the therapeutic effect of tranexamic acid.
- 22 June 2020
- Published byĀ Taylor & FrancisĀ inĀ Journal of Dermatological Treatment
- Vol.Ā 33 Ā (2) , 798-804
Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma
Background: Tranexamic acid is a promising drug for melasma treatment, but its topical formulation has limited efficacy. Its use as liposome based cream or in combination with other modalities might help to achieve better results. Objective: Comparing efficacy of topical tranexamic acid 5% in liposome base alone versus its combination with intradermal platelet rich plasma (PRP) for melisma treatment. Methods: Forty female patients with melasma were divided randomly into 2 equal groups who were treated with topical tranexamic acid 5% cream twice daily for 12 weeks and group B received additional intradermal injections of PRP every 3 weeks throughout the treatment period. Evaluation was done through modified MASI score and patient satisfaction after one month from the end of treatment. Results: Both groups showed significant improvement of modified MASI score after treatment. Significantly better treatment response and patient satisfaction were detected in patients of group B (p = .024, .029). The side effects of PRP were mild and tolerable and tranexamic acid was well tolerated. Conclusion: 5% topical tranexamic acid in liposome base is thought to be safe and effective modality for treatment of melasma. PRP is advisable as an autologous safe elixir which boosts the therapeutic effect of tranexamic acid.
- 4 March 2020
- Published byĀ Taylor & FrancisĀ inĀ Journal of Dermatological Treatment
- Vol.Ā 33 Ā (1) , 150-156
Combined intralesional triamcinolone acetonide and platelet rich plasma versus intralesional triamcinolone acetonide alone in treatment of keloids
Background: Keloids are benign fibro-proliferative growths occurring after skin injury or spontaneously. Intralesional triamcinolone acetonide (TA) is their first-line therapy, but commonly associated with side effects or recurrence. Platelet rich plasma (PRP) is an autologous blood-derived product with promising results in improving wound healing with lower keloid occurrence. Objective: comparing the efficacy of combined intralesional TA and PRP versus TA alone in keloids treatment. Methods: 40 patients with keloids were divided randomly into two equal groups (A and B). Both groups received intralesional TA (20 mg/ml) for 4 sessions, three weeks apart. Group A patients received additional intralesional PRP one week after TA injections. Evaluation was done after 3 months of follow up by Vancouver scar scale (VSS) and verbal rating scale (VRS) for pain and itching. Results: Both groups showed significant improvement in all parameters of VSS and VRS in comparison with baseline. Significantly better improvement in height, pigmentation, pliability and overall VSS was detected in patients of group A. A significantly higher incidence of post-TA atrophy and hypopigmentation was observed in group B. Conclusions: Combining intralesional PRP with TA could yield cosmetically better outcomes in keloid treatment with lower incidence of TA-induced side effects especially atrophy and hypopigmentation.
- 4 March 2020
- Published byĀ Taylor & FrancisĀ inĀ Journal of Dermatological Treatment
- Vol.Ā 33 Ā (1) , 150-156
Combined intralesional triamcinolone acetonide and platelet rich plasma versus intralesional triamcinolone acetonide alone in treatment of keloids
Background: Keloids are benign fibro-proliferative growths occurring after skin injury or spontaneously. Intralesional triamcinolone acetonide (TA) is their first-line therapy, but commonly associated with side effects or recurrence. Platelet rich plasma (PRP) is an autologous blood-derived product with promising results in improving wound healing with lower keloid occurrence. Objective: comparing the efficacy of combined intralesional TA and PRP versus TA alone in keloids treatment. Methods: 40 patients with keloids were divided randomly into two equal groups (A and B). Both groups received intralesional TA (20 mg/ml) for 4 sessions, three weeks apart. Group A patients received additional intralesional PRP one week after TA injections. Evaluation was done after 3 months of follow up by Vancouver scar scale (VSS) and verbal rating scale (VRS) for pain and itching. Results: Both groups showed significant improvement in all parameters of VSS and VRS in comparison with baseline. Significantly better improvement in height, pigmentation, pliability and overall VSS was detected in patients of group A. A significantly higher incidence of post-TA atrophy and hypopigmentation was observed in group B. Conclusions: Combining intralesional PRP with TA could yield cosmetically better outcomes in keloid treatment with lower incidence of TA-induced side effects especially atrophy and hypopigmentation.
- 12 November 2019
- Published byĀ Taylor & FrancisĀ inĀ Journal of Dermatological Treatment
- Vol.Ā 32 Ā (6) , 663-668
A comparative study of intralesional injection of Candida albicans antigen, bleomycin and 5-fluorouracil for treatment of plane warts
Background: Several therapeutic modalities for treatment of verruca plana (VP) are available, but none has achieved complete cure in all cases with associated risk of side effects. Objective: To evaluate efficacy and safety of intralesional injection of candida albicans (C.albican) antigen, bleomycin and 5- fluorouracil (5-FU) in treatment of VP. Methods: 60 patients with VP were randomly divided into 3 equal groups who were treated using C.albicans antigen, bleomycin or 5- FU injections every 2 weeks till complete clearance of the lesions or for a maximum of 4 sessions and followed up for additional 8 weeks. Results: A statistically significant higher incidence of complete response was achieved with bleomycin (85%) than C.albicans antigen (60%) which was higher than 5-FU (45%) with a significantly less number of required sessions to achieve best results with bleomycin and candida antigen than 5-FU. Conclusions: C.albicans antigen, bleomycin and 5-FU are helpful modalities for treatment of VP. Bleomycin was the most effective, followed by C.albicans antigen then 5-FU (least effective). Single injection site, clearance of distant warts and decreased incidence of new lesion development - insitu or elsewhere - are additional merits of C.albicans immunotherapy. These modalities are cheap with only transient adverse effects.
- 12 November 2019
- Published byĀ Taylor & FrancisĀ inĀ Journal of Dermatological Treatment
- Vol.Ā 32 Ā (6) , 663-668
A comparative study of intralesional injection of Candida albicans antigen, bleomycin and 5-fluorouracil for treatment of plane warts
Background: Several therapeutic modalities for treatment of verruca plana (VP) are available, but none has achieved complete cure in all cases with associated risk of side effects. Objective: To evaluate efficacy and safety of intralesional injection of candida albicans (C.albican) antigen, bleomycin and 5- fluorouracil (5-FU) in treatment of VP. Methods: 60 patients with VP were randomly divided into 3 equal groups who were treated using C.albicans antigen, bleomycin or 5- FU injections every 2 weeks till complete clearance of the lesions or for a maximum of 4 sessions and followed up for additional 8 weeks. Results: A statistically significant higher incidence of complete response was achieved with bleomycin (85%) than C.albicans antigen (60%) which was higher than 5-FU (45%) with a significantly less number of required sessions to achieve best results with bleomycin and candida antigen than 5-FU. Conclusions: C.albicans antigen, bleomycin and 5-FU are helpful modalities for treatment of VP. Bleomycin was the most effective, followed by C.albicans antigen then 5-FU (least effective). Single injection site, clearance of distant warts and decreased incidence of new lesion development - insitu or elsewhere - are additional merits of C.albicans immunotherapy. These modalities are cheap with only transient adverse effects.